OM - Alnylam Crispr Therapeutics among Goldman's biopharma M&A targets for 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Assets Basket, which now consists of 24 names where analysts see a greater than 15% chance of M&A in the next 12 months. Goldman sees total 2022 biopharma M&A capacity at $617B, up 20% from its 2021 estimate. Potential buyers are likely to focus more on "bolt-ons," rather than large "transformative deals" and acquisitions will likely be focused on areas such as  oncology, inflammation, and new technologies such as RNAi, gene therapy/editing and protein degradation. "Rather than waiting for inbound expressions of interest from strategic acquirers, we think that the current environment could lead some biotech management teams and boards to contemplate actively putting companies up for sale or seeking a merger partner,"  Goldman analysts

For further details see:

Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022